Literature DB >> 7556525

Stage- and lineage-specific expression of the HOXA10 homeobox gene in normal and leukemic hematopoietic cells.

H J Lawrence1, G Sauvageau, N Ahmadi, A R Lopez, M M LeBeau, M Link, K Humphries, C Largman.   

Abstract

There is growing evidence that the HOX homeobox-containing transcription factors are differentially expressed during hematopoiesis. We have previously demonstrated that the HOXA10 gene is expressed in unfractionated normal marrow and in immortalized leukemic cell lines with myelomonocytic features, but not in cell lines with lymphoid or erythroid features. To gain insights into the patterns of activation of this gene during hematopoietic differentiation, we have examined HOXA10 expression in CD34+ and CD34- subfractions of normal marrow and normal peripheral blood, as well as samples from patients with a variety of acute and chronic leukemias. HOXA10 is strongly expressed in CD34+ normal marrow cells, markedly downregulated in CD34- marrow cells, and inactive in mature neutrophils, monocytes, and lymphocytes. HOXA10 is expressed in all types of acute myelogenous leukemia (AML) with the notable exception of acute promyelocytic leukemia (AML-M3). HOXA10 message is observed in chronic myelogenous leukemia (CML) but appears to be reduced in accelerated phase and blast crisis, particularly lymphoid blast crisis. With rare exception, HOXA10 expression is not observed in samples of acute or chronic lymphoid leukemias. Normal marrow and patient samples appear to contain a single transcript which encodes a full-length homeobox-containing protein, while immortalized cell lines contain an additional alternatively spliced transcript. These studies indicate that HOXA10 expression is restricted to early stages of myeloid differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7556525

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  19 in total

1.  HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells.

Authors:  W F Shen; S Rozenfeld; A Kwong; L G Köm ves; H J Lawrence; C Largman
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors:  Paul M Ayton; Michael L Cleary
Journal:  Genes Dev       Date:  2003-09-02       Impact factor: 11.361

3.  Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.

Authors:  Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

4.  The oncoprotein E2A-Pbx1a collaborates with Hoxa9 to acutely transform primary bone marrow cells.

Authors:  U Thorsteinsdottir; J Krosl; E Kroon; A Haman; T Hoang; G Sauvageau
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

5.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

Review 6.  Transcriptional regulation during myelopoiesis.

Authors:  N Lenny; J J Westendorf; S W Hiebert
Journal:  Mol Biol Rep       Date:  1997-08       Impact factor: 2.316

Review 7.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

8.  HoxA10 influences protein ubiquitination by activating transcription of ARIH2, the gene encoding Triad1.

Authors:  Hao Wang; Ling Bei; Chirag A Shah; Elizabeth Horvath; Elizabeth A Eklund
Journal:  J Biol Chem       Date:  2011-03-28       Impact factor: 5.157

9.  Global analysis of genes regulated by HOXA10 in decidualization reveals a role in cell proliferation.

Authors:  Z Lu; J Hardt; J J Kim
Journal:  Mol Hum Reprod       Date:  2008-05-02       Impact factor: 4.025

10.  HOXA9 is required for survival in human MLL-rearranged acute leukemias.

Authors:  Joerg Faber; Andrei V Krivtsov; Matthew C Stubbs; Renee Wright; Tina N Davis; Marry van den Heuvel-Eibrink; Christian M Zwaan; Andrew L Kung; Scott A Armstrong
Journal:  Blood       Date:  2008-12-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.